ADICET BIO INC
ACETNASDAQTrading Snapshot
- Day Range
- $8.17 – $8.28
- 52-Week Range
- $6.01 – $17.44
- Volume
- $2.93B
- Avg Volume
- $2.43B
- Shares Outstanding
- 9.3M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-9.21
- Dividend Yield
- 0.00%
Why Investors Own ACET
- ✓High-growth profile — revenue up +54.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 33% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ADICET BIO INC
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $90
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $100 to $90.
Adicet Bio Q2 EPS $(1.99) Beats $(2.03) Estimate
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.03) by 1.97 percent. This is a 63.42 percent increase over losses of $(5.44) per share from the